Comparison of two rapid influenza A/B test kits with reference methods showing high specificity and sensitivity for influenza A infection

Publisher Website
Google Scholar
Abstract
The rapid detection of influenza viruses is important for forming preventative strategies, directing initiation of anti‐viral therapy, detecting potential avian influenza viruses, and excluding influenza‐like pathogens, such as SARS. The ImmunoCard STAT! Flu A and B Plus test (Meridian Bioscience, Cincinnati, OH) is a new point of care (POC) test utilizing influenza‐specific monoclonal antibodies for rapid diagnosis. The performance of this assay was compared to the established POC Binax NowFlu A and NowFlu B test, and the reference diagnostic standards of viral culture, indirect immunofluorescence (IFA), and RT‐PCR where appropriate. Testing of nasopharyngeal aspirates (NPA) from children, throat swabs, and nasal swabs from adults indicated ImmunoCard STAT! specificity of 98% and 100% for influenza A and B, respectively in 224 specimens. The Binax test showed specificity of 99% and 100%, respectively for influenza A and B. Sensitivity results were identical for both rapid detection kits (80% and 47% for Flu A and B, respectively). Overall results were very similar for both testing devices with the advantage of ImmunoCard STAT! Flu A and B Plus test detecting influenza A and B with sharp and easy to read results. J. Med. Virol. 78:619–622, 2006.

This publication has 13 references indexed in Scilit: